Trials
2 active
6 in total · 2 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Cachexia (2 trials), Metastatic Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)
- Main trialPhase 2/3
- “Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.”In the company’s words, NCT06989437 on ClinicalTrials.gov
- Other names
- PF-06946860
Other drugs for Cachexia
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- VisugromabCatalYm GmbH · Phase 2/3
- RilogrotugAVEO Pharmaceuticals, Inc. · Phase 2/3
- SXRNJiangsu Guiqiong Pharmaceutical Co., Ltd. · Phase 2
- DS010Dartsbio Pharmaceuticals Ltd. · Phase 1/2
- TCMCB07Endevica Bio · Phase 2
Coming up2
- 23 Jan 2028Phase 2/3 trial completes · ClinicalTrials.gov
- 6 May 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 23 Jan 2028 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | |
| Phase 1Not yet recruiting | 6 May 2028 | A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss | |
| Phase 2Completed | 13 Mar 2024 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 | |
| Phase 1Completed | 30 Mar 2022 | Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. | |
| Phase 1Completed | 14 Apr 2022 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | |
| Phase 1Completed | 7 Jul 2023 | A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026